These new GBM cell lines were classified according to the guidelines proposed by WHO in their 2016 CNS tumours classification [5], the “Hotspot” mutation region sequences of IDH1, IDH2 and TERT were determined by Sanger sequencing, and the electropherograms obtained were studied to detect the described mutations: in IDH1 R132, in IDH2 R172, and the C225T or C250T TERT promoter region [28,32]. The gene discussed is IDH1; the disease is glioblastoma.